41 results on '"van Zandwijk, Nico"'
Search Results
2. A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC).
- Author
-
van Zandwijk, Nico and Frank, Arthur L.
- Subjects
- *
LUNG cancer - Published
- 2024
- Full Text
- View/download PDF
3. Lung cancer: Removing toxic dust from our environment.
- Author
-
van Zandwijk, Nico, Marshall, Henry M., and Fong, Kwun M.
- Subjects
- *
LUNG cancer , *DUST - Abstract
See relatedarticle [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
- Author
-
van Zandwijk, Nico, Pavlakis, Nick, Kao, Steven C, Linton, Anthony, Boyer, Michael J, Clarke, Stephen, Huynh, Yennie, Chrzanowska, Agata, Fulham, Michael J, Bailey, Dale L, Cooper, Wendy A, Kritharides, Leonard, Ridley, Lloyd, Pattison, Scott T, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, and Reid, Glen
- Subjects
- *
MICRORNA , *MESOTHELIOMA , *DRUG dosage , *RADIOLOGY , *ONCOLOGY - Abstract
Summary Background TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma. Methods In this first-in-man, open-label, dose-escalation phase 1 trial at three major cancer centres in Sydney (NSW, Australia), we recruited adults (aged ≥18 years) with a confirmed diagnosis of malignant pleural mesothelioma, measurable disease, radiological signs of progression after previous chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 3 months or more, immunohistochemical evidence of tumour EGFR expression, and adequate bone marrow, liver, and renal function. Patients were given TargomiRs via 20 min intravenous infusion either once or twice a week (3 days apart) in a traditional 3 + 3 dose-escalation design in five dose cohorts. The dose-escalation steps planned were 5 × 10 9 , 7 × 10 9 , and 9 × 10 9 TargomiRs either once or twice weekly, but after analysis of data from the first eight patients, all subsequent patients started protocol treatment at 1 × 10 9 TargomiRs. The primary endpoints were to establish the maximum tolerated dose of TargomiRs as measured by dose-limiting toxicity, define the optimal frequency of administration, and objective response (defined as the percentage of assessable patients with a complete or partial response), duration of response (defined as time from the first evidence of response to disease progression in patients who achieved a response), time to response (ie, time from start of treatment to the first evidence of response) and overall survival (defined as time from treatment allocation to death from any cause). Analyses were based on the full analysis set principle, including every patient who received at least one dose of TargomiRs. The study was closed for patient entry on Jan 3, 2017, and registered with ClinicalTrials.gov , number NCT02369198 , and the Australian Registry of Clinical Trials, number ACTRN12614001248651. Findings Between Sept 29, 2014, and Nov 24, 2016, we enrolled 27 patients, 26 of whom received at least one TargomiR dose (one patient died before beginning treatment). Overall, five dose-limiting toxicities were noted: infusion-related inflammatory symptoms and coronary ischaemia, respectively, in two patients given 5 × 10 9 TargomiRs twice weekly; anaphylaxis and cardiomyopathy, respectively, in two patients given 5 × 10 9 TargomiRs once weekly but who received reduced dexamethasone prophylaxis; and non-cardiac pain in one patient who received 5 × 10 9 TargomiRs once weekly. We established that 5 × 10 9 TargomiRs once weekly was the maximum tolerated dose. TargomiR infusions were accompanied by transient lymphopenia (25 [96%] of 26 patients), temporal hypophosphataemia (17 [65%] of 26 patients), increased aspartate aminotransferase or alanine aminotranferase (six [23%] of 26 patients), and increased alkaline phosphatase blood concentrations (two [8%]). Cardiac events occurred in five patients: three patients had electrocardiographic changes, one patient had ischaemia, and one patient had Takotsubo cardiomyopathy. Of the 22 patients who were assessed for response by CT, one (5%) had a partial response, 15 (68%) had stable disease, and six (27%) had progressive disease. The proportion of patients who achieved an objective response was therefore one (5%) of 22, and the duration of the objective response in that patient was 32 weeks. Median overall survival was 200 days (95% CI 94–358). During the trial, 21 deaths occurred, of which 20 were related to tumour progression and one was due to bowel perforation. Interpretation The acceptable safety profile and early signs of activity of TargomiRs in patients with malignant pleural mesothelioma support additional studies of TargomiRs in combination with chemotherapy or immune checkpoint inhibitors. Funding Asbestos Diseases Research Foundation. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins αvβ3 and αvβ5.
- Author
-
Cheng, Ngan Ching, van Zandwijk, Nico, and Reid, Glen
- Subjects
- *
MESOTHELIOMA , *CANCER cells , *INTEGRINS , *ASBESTOS , *CANCER invasiveness , *CHEST (Anatomy) , *BIOLOGICAL membranes , *HETERODIMERS - Abstract
Malignant pleural mesothelioma (MPM) is an almost invariably fatal, asbestos-related malignancy arising from the mesothelial membrane lining the thoracic cavities. Despite some improvements in treatment, therapy is not considered curative and median survival following diagnosis is less than 1 year. Although still classed as a rare cancer, the incidence of MPM is increasing, and the limited progress in treating the disease makes the identification of new therapies a priority. As there is evidence for expression of the integrins αvβ3 and αvβ5 in MPM, there is a rationale for investigating the effects on MPM of cilengitide, a synthetic peptide inhibitor of integrin αv heterodimer with high specificity for αvβ3 and αvβ5. In mesothelial cells (MC) and 7 MPM cell lines, growth inhibition by cilengitide was associated with the expression level of its target integrins. Furthermore, cilengitide caused cell detachment and subsequent death of anoikis-sensitive cells. It also suppressed invasion of MPM cells in monolayer and three-dimensional cultures. Gene knockdown experiments indicated that these effects of cilengitide were, at least partly, due to antagonism of αvβ3 and αvβ5. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Chemoprevention in lung carcinogenesis – An overview
- Author
-
van Zandwijk, Nico
- Subjects
- *
CHEMOPREVENTION , *LUNG cancer , *CIGARETTE smokers , *TOBACCO - Abstract
Abstract: Lung cancer ranks among the most commonly occurring malignancies and is currently the leading cause of cancer-related death worldwide. This is due to its late diagnosis and relative resistance to standard oncological treatment approaches. The heavy burden of lung cancer and its treatment resistance have elicited an intense interest in the promising approach of chemoprevention. Chemoprevention is defined as a pharmacologic intervention to suppress or reverse the carcinogenic process and the lung is one of the most studied sites for cancer chemoprevention. This review, with a short update on pulmonary carcinogenesis, will summarize the available knowledge of chemoprevention trials and agents with a preventive potential in the ‘lung field’. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
7. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.
- Author
-
van Zandwijk, Nico, Dalesio, Otilia, van Zandwijk, N, Dalesio, O, Pastorino, U, de Vries, N, and van Tinteren, H
- Subjects
- *
CHEMOPREVENTION , *THERAPEUTIC use of vitamin A , *HEAD & neck cancer , *LUNG cancer - Abstract
Background: Preclinical evidence suggests that retinoids and antioxidants may prevent or delay the occurrence of cancer in the upper or lower airways, but such effects have not been reliably established in clinical studies. To assess the chemopreventive effects of vitamin A (retinyl palmitate) and N-acetylcysteine, we conducted a large randomized intervention study in patients with head and neck cancer or with lung cancer, most of whom had a history of smoking.Methods: From June 1988 through July 1994, a total of 2592 patients (60% with head and neck cancer and 40% with lung cancer) were randomly assigned to receive 1) retinyl palmitate (300000 IU daily for 1 year followed by 150000 IU for a 2(nd) year), 2) N-acetylcysteine (600 mg daily for 2 years), 3) both compounds, or 4) no intervention. All statistical tests were two-sided.Results: Of the patients, 93.5% had smoked tobacco at sometime in their lives (and 25% continued to smoke after cancer diagnosis). After a median follow-up of 49 months, 916 patients were reported with an event (recurrence, second primary tumor, or death). No statistically significant difference was observed in overall survival or event-free survival between patients who received retinyl palmitate and patients who did not. Similarly, no difference was seen in overall survival or event-free survival between patients who received N-acetylcysteine and patients who did not. There was a lower incidence of second primary tumors in the no intervention arm, but the difference was not statistically significant.Conclusion: A 2-year supplementation of retinyl palmitate and/or N-acetylcysteine resulted in no benefit-in terms of survival, event-free survival, or second primary tumors-for patients with head and neck cancer or with lung cancer, most of whom were previous or current smokers. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
8. Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer.
- Author
-
Ke, Helen, Kao, Steven, van Zandwijk, Nico, Rasko, John E.J., and Yeo, Dannel
- Subjects
- *
LUNG cancer , *IMMUNE checkpoint inhibitors , *EARLY diagnosis , *MEDICAL screening , *BIOLOGY - Abstract
[Display omitted] • Diagnosing asbestos-related lung cancer (ARLC) is challenging. • Circulating tumor cells (CTCs) are a promising liquid biopsy biomarker. • CTCs could improve screening high-risk populations including those exposed to asbestos. • CTCs could provide molecular insights into ARLC, improving diagnosis and patient management. Asbestos-Related Lung Cancer (ARLC) presents ongoing diagnostic challenges despite improved imaging technologies. The long latency period, coupled with limited access to occupational and environmental data along with the confounding effects of smoking and other carcinogens adds complexity to the diagnostic process. Compounding these challenges is the absence of a specific histopathologic or mutational signature of ARLC. A correlation between PD-L1 expression and response to immune checkpoint inhibition has not yet been proven. Thus, new biomarkers are needed to allow accurate diagnoses of ARLC, to enable prognostication and to offer personalized treatments. Liquid biopsies, encompassing circulating DNA and circulating tumor cells (CTCs), have gained attention as novel diagnostic methods in lung cancer to screen high-risk populations including those exposed to asbestos. CTCs can be enumerated and molecularly profiled to provide predictive and prognostic information. CTC studies have not been undertaken in populations at risk of ARLC to date. The potential of CTCs to provide real-time molecular insight into ARLC biology may significantly improve the diagnosis and management of ARLC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
- Author
-
van Zandwijk, Nico, Pavlakis, Nick, Kao, Steven C, Linton, Anthony, Boyer, Michael J, Clarke, Stephen, Huynh, Yennie, Chrzanowska, Agata, Fulham, Michael J, Bailey, Dale L, Cooper, Wendy A, Kritharides, Leonard, Ridley, Lloyd, Pattison, Scott T, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, and Reid, Glen
- Subjects
- *
CANCER relapse , *CANCER treatment , *CLINICAL trials , *COMPARATIVE studies , *DRUG administration , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *IMMUNOHISTOCHEMISTRY , *INTRAVENOUS therapy , *LONGITUDINAL method , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *MESOTHELIOMA , *NEEDLE biopsy , *PATIENT safety , *PROGNOSIS , *RESEARCH , *RISK assessment , *RNA , *SURVIVAL analysis (Biometry) , *PLEURAL tumors , *EVALUATION research , *SPECIALTY hospitals , *TREATMENT effectiveness , *PATIENT selection , *KAPLAN-Meier estimator - Abstract
Background: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma.Methods: In this first-in-man, open-label, dose-escalation phase 1 trial at three major cancer centres in Sydney (NSW, Australia), we recruited adults (aged ≥18 years) with a confirmed diagnosis of malignant pleural mesothelioma, measurable disease, radiological signs of progression after previous chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 3 months or more, immunohistochemical evidence of tumour EGFR expression, and adequate bone marrow, liver, and renal function. Patients were given TargomiRs via 20 min intravenous infusion either once or twice a week (3 days apart) in a traditional 3 + 3 dose-escalation design in five dose cohorts. The dose-escalation steps planned were 5 × 109, 7 × 109, and 9 × 109 TargomiRs either once or twice weekly, but after analysis of data from the first eight patients, all subsequent patients started protocol treatment at 1 × 109 TargomiRs. The primary endpoints were to establish the maximum tolerated dose of TargomiRs as measured by dose-limiting toxicity, define the optimal frequency of administration, and objective response (defined as the percentage of assessable patients with a complete or partial response), duration of response (defined as time from the first evidence of response to disease progression in patients who achieved a response), time to response (ie, time from start of treatment to the first evidence of response) and overall survival (defined as time from treatment allocation to death from any cause). Analyses were based on the full analysis set principle, including every patient who received at least one dose of TargomiRs. The study was closed for patient entry on Jan 3, 2017, and registered with ClinicalTrials.gov, number NCT02369198, and the Australian Registry of Clinical Trials, number ACTRN12614001248651.Findings: Between Sept 29, 2014, and Nov 24, 2016, we enrolled 27 patients, 26 of whom received at least one TargomiR dose (one patient died before beginning treatment). Overall, five dose-limiting toxicities were noted: infusion-related inflammatory symptoms and coronary ischaemia, respectively, in two patients given 5 × 109 TargomiRs twice weekly; anaphylaxis and cardiomyopathy, respectively, in two patients given 5 × 109 TargomiRs once weekly but who received reduced dexamethasone prophylaxis; and non-cardiac pain in one patient who received 5 × 109 TargomiRs once weekly. We established that 5 × 109 TargomiRs once weekly was the maximum tolerated dose. TargomiR infusions were accompanied by transient lymphopenia (25 [96%] of 26 patients), temporal hypophosphataemia (17 [65%] of 26 patients), increased aspartate aminotransferase or alanine aminotranferase (six [23%] of 26 patients), and increased alkaline phosphatase blood concentrations (two [8%]). Cardiac events occurred in five patients: three patients had electrocardiographic changes, one patient had ischaemia, and one patient had Takotsubo cardiomyopathy. Of the 22 patients who were assessed for response by CT, one (5%) had a partial response, 15 (68%) had stable disease, and six (27%) had progressive disease. The proportion of patients who achieved an objective response was therefore one (5%) of 22, and the duration of the objective response in that patient was 32 weeks. Median overall survival was 200 days (95% CI 94-358). During the trial, 21 deaths occurred, of which 20 were related to tumour progression and one was due to bowel perforation.Interpretation: The acceptable safety profile and early signs of activity of TargomiRs in patients with malignant pleural mesothelioma support additional studies of TargomiRs in combination with chemotherapy or immune checkpoint inhibitors.Funding: Asbestos Diseases Research Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
10. Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends.
- Author
-
Soeberg, Matthew J., Leigh, James, and van Zandwijk, Nico
- Subjects
- *
MESOTHELIOMA , *TOXICOLOGY of asbestos , *RIEBECKITE , *ASBESTOS & health , *EPIDEMIOLOGY - Abstract
Australia is known to have had the highest per-capita asbestos consumption level of any nation, reaching a peak in the 1970s. Although crocidolite was effectively banned in the late 1960s, and amosite use ceased in the mid 1980s, a complete asbestos ban was not implemented until 2003. This resulted in an epidemic of asbestos-related disease, which has only now reached its peak. Between 1982 and 2011, 13,036 individuals were newly diagnosed with malignant mesothelioma, with 690 diagnosed in 2011. A further 778 cases were identified between 1945 and 1981 from retrospective searches and the first 2 years of the Australian Mesothelioma Program. The age-standardized malignant mesothelioma incidence rate has leveled off in the last 10 years (2.8 per 100,000 in 2011). There has been a marked increase over time in the age-specific incidence rates for individuals aged 75 years or older. Data from the current Australian Mesothelioma Registry on asbestos exposure history in Australia is available for 449 subjects diagnosed between July 1, 2010, and April 1, 2015. This asbestos exposure history data show that 60% (n = 268) of cases had probable or possible occupational asbestos exposure, with trade-based jobs being the most frequent sources of occupational asbestos exposure. In addition, out of the 449 cases, 377 were recorded as having probable or possible nonoccupational asbestos exposure. Continuous vigilance toward changes over time in the settings in which people are exposed to asbestos and in the descriptive epidemiology of malignant mesothelioma is recommended to enable a comprehensive understanding of the current and future impact of asbestos-related diseases in Australia. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
11. Asbestos‐related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation.
- Author
-
Hyland, Rebecca A, Chrzanowska, Agata, Hannaford‐Turner, Kirsty, Davis, Alexander, Ke, Helen, Bradbury, Lauren, Nagrial, Adnan, McCaughan, Brian, Hui, Rina, van Zandwijk, Nico, Takahashi, Ken, and Kao, Steven C
- Subjects
- *
LUNG cancer , *WORKERS' compensation , *SURVIVAL rate , *OLDER patients , *OVERALL survival - Abstract
Background and objectives: Due to difficulties in identifying sufficient‐sized cohorts there remains uncertainty about prognostic and clinical differences that may be unique to asbestos‐related lung cancer (ARLC). In this study, we use the Helsinki Criteria to define a group of ex‐workers with lung cancer attributable to asbestos exposure and investigate differences that may exist. Methods: A total of 529 patients seeking workers' compensation for their lung cancer were assigned to either ARLC or the non‐ARLC based on parameters defined in the Helsinki Criteria. Clinical and survival details were collected and analyzed. Results: In our study population, ARLC patients were on average older (72.1 ± 7.8) than non‐ARLC patients (66.5 ± 10.2, P < 0.001) and were more likely to be diagnosed as a result of incidental findings or screening program (P < 0.001). The groups were similar in terms of clinical characteristics with the only difference being that plaques were more prevalent among ARLC patients (P < 0.001). Differences were observed for median overall survival (OS), ARLC (9 months) and non‐ARLC (13 months, P = 0.005), as well for treatment (P = 0.01). After adjusting for age, however, these differences disappeared. Conclusions: Age at diagnosis, pleural plaques, and asymptomatic presentation were the attributes that we identified as significantly different between asbestos‐related cancer and other lung cancers. In this cohort, ARLC patients were older diagnosis and with worse overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. New methods for early diagnosis of lung cancer
- Author
-
van Zandwijk, Nico
- Subjects
- *
LUNG cancer diagnosis , *CANCER treatment - Abstract
The recent promising results with low-dose CT have stimulated the revival of the scientific discussion on screening for early lung cancer and mark the end of a significant period with lack of progress. At the same time positron emission tomography has quickly shown its value as a staging tool. Also new endobronchial techniques such as autofluorescence bronchoscopy and endobronchial ultrasonography have shown remarkably increased sensitivity when used by experienced hands. Cytopathological risk markers in sputum are being developed and it is expected that combinations of these new diagnostic methods will help to increase the identification of asymptomatic lung cancer patients and turn into better survival figures. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
13. Circulating microRNAs: Association with disease and potential use as biomarkers
- Author
-
Reid, Glen, Kirschner, Michaela B., and van Zandwijk, Nico
- Subjects
- *
NON-coding RNA , *BIOMARKERS , *GENE expression , *PATHOLOGICAL physiology , *CEREBROVASCULAR disease , *BLOOD plasma , *SERUM - Abstract
Abstract: The control of gene expression by microRNAs influences many cellular processes and has been implicated in the control of many (patho)physiological states. Recently, microRNAs have been detected in serum and plasma, and circulating microRNA profiles have now been associated with a range of different tumour types, diseases such as stroke and heart disease, as well as altered physiological states such as pregnancy. Here we review the disease-specific profiles of circulating microRNAs, and the methodologies used for their detection and quantification. We also discuss possible functions of circulating microRNAs and their potential as non-invasive biomarkers. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
14. Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study
- Author
-
Heigener, David F., Wu, Yi-Long, van Zandwijk, Nico, Mali, Pekka, Horwood, Keith, and Reck, Martin
- Subjects
- *
SMALL cell lung cancer , *DRUG efficacy , *EPIDERMAL growth factor , *CELL receptors , *PROTEIN-tyrosine kinases , *PLACEBOS - Abstract
Abstract: Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase activity that significantly prolongs overall survival in patients with non-small-cell lung cancer (NSCLC), and improves symptom control and quality of life compared with placebo. The safety and efficacy of erlotinib has been investigated in a large, international, phase IV, open-label study (TRUST) in patients (n =6665) with advanced stage IIIB/IV NSCLC. An analysis of efficacy and safety outcomes is reported for patients receiving erlotinib as second-line therapy in TRUST (n =3224). Best response data were available for all 3224 patients. Complete response, partial response and stable disease were achieved in 25 (<1%), 368 (14%) and 1444 (54%) patients, respectively, for a disease control rate of 68%. Median progression-free and overall survivals were 13.6 weeks and 8.6 months, respectively; 1-year survival was 39.4%. Safety data were available for all patients. Of these, 389 patients (12%) had an erlotinib-related adverse event (AE) other than pre-specified AEs defined in the protocol; only 96 patients (3%) had an erlotinib-related AE ≥grade 3. Of 1376 patients (43%) with serious AEs (SAEs), only 122 (4%) had treatment-related SAEs and most were gastrointestinal disorders (mainly diarrhoea and nausea). No treatment-related SAE occurred in ≥1% of patients. Data on the incidence of erlotinib-related rash were collected for all patients, 2302 (71%) of whom experienced rash. Of these rash events, 83% were of grade 1/2. These data confirm the good efficacy and tolerability of second-line erlotinib in a broad range of patients with NSCLC. Clinical trial number: NCT00949910. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
15. Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
- Author
-
Yeo, Dannel, Castelletti, Laura, van Zandwijk, Nico, and Rasko, John E. J.
- Subjects
- *
BIOMARKERS , *MESOTHELIOMA , *MONOCLONAL antibodies , *PLEURAL tumors , *IMMUNOTHERAPY - Abstract
Simple Summary: Mesothelioma is a deadly disease with a dismal prognosis. Since its discovery, mesothelin, a cell surface protein, has been a promising biomarker and therapeutic target due to its overexpression in mesothelioma and limited expression in normal cells. This review summarizes the clinical studies that have examined mesothelin as a biomarker and therapeutic target in mesothelioma and explores future perspectives in its role to improve patient management. Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM. Many other solid cancers overexpress MSLN, and this is associated with worse survival rates. However, this association has not been found in MPM, and the exact biological role of MSLN in MPM requires further exploration. Here, we discuss the current research on the diagnostic and prognostic value of MSLN in MPM patients. Furthermore, MSLN has become an attractive immunotherapy target in MPM, where better treatment strategies are urgently needed. Several MSLN-targeted monoclonal antibodies, antibody–drug conjugates, immunotoxins, cancer vaccines, and cellular therapies have been tested in the clinical setting. The biological rationale underpinning MSLN-targeted immunotherapies and their potential to improve MPM patient outcomes are reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone
- Author
-
van den Berg, Remco M., Teertstra, H. Jelle, van Zandwijk, Nico, van Tinteren, Harm, Visser, Christien, Pasic, Arifa, Sutedja, Thomas G., Baas, Paul, Golding, Richard P., Postmus, Pieter E., and Smit, Egbert F.
- Subjects
- *
LUNG tumors , *ADRENOCORTICAL hormones , *TUMOR growth , *HEALTH risk assessment - Abstract
Summary: Introduction: In animal models of lung carcinogenesis, inhaled corticosteroids appear to reduce the number of new lung tumors. In a trial of budesonide in smokers with bronchial dysplasia, the proportion of indeterminate CT detected pulmonary nodules that resolved was larger in the treatment group. We performed a secondary analysis of CT data of subjects at risk of lung cancer enrolled in a chemoprevention trial of fluticasone. Methods: Subjects with bronchial squamous metaplasia or dysplasia had a baseline chest CT scan. They were randomized to fluticasone or a placebo. After 6 months a repeat CT was performed and the change in number and size of nodules was evaluated. Results: Two hundred and one subjects were screened. Of the 108 volunteers included in the study, 74 were male, mean age was 53 years and mean number of pack years 48. Baseline: 35 subjects had 91 nodules in total, 62% <4mm. In the fluticasone arm more subjects had a decrease and fewer had an increase in number of nodules, however this trend did not reach statistical significance. Conclusion: In this preliminary study there was a tendency of nodules to resolve, however, studies with CT detected nodules as inclusion criterion are needed. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
17. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
- Author
-
Belderbos, José, Uitterhoeve, Lon, van Zandwijk, Nico, Belderbos, Huub, Rodrigus, Patrick, van de Vaart, Paul, Price, Allan, van Walree, Nico, Legrand, Catherine, Dussenne, Sonia, Bartelink, Harry, Giaccone, Giuseppe, and Koning, Caro
- Subjects
- *
DRUG therapy , *RADIOTHERAPY , *SMALL cell lung cancer , *LUNG cancer , *CANCER patients - Abstract
Abstract: A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients. Methods: One hundred and fifty-eight patients were randomised to receive two courses of Gemcitabine (1250mg/m2 days 1, 8) and Cisplatin (75mg/m2 day 2) prior to, or daily low-dose Cisplatin (6mg/m2) concurrent with radiotherapy, consisting of 24 fractions of 2.75Gy in 32 days, with a total dose of 66Gy. Results: Acute haematological toxicity grade 3/4 was more pronounced in the sequential (S) (30% versus 6%), oesophagitis grade 3/4 more frequent in the concurrent (C) arm (5% versus 14%). Late oesophagitis grade 3 was 4% (S and C), pneumonitis grade 3/4 14% (S) and 18% (C). Because of the poor power of the study no significant differences in median survival (MS), overall survival (OS) and progression-free survival (PFS) could be detected. MS was 16.2 (S) and 16.5 (C) months, 2-year OS was 34% (S) and 39% (C), 3-year OS was 22% (S) and 34% (C). Conclusion: Radiotherapy 66Gy given concurrently with daily low-dose Cisplatin or after two courses of Gemcitabine/Cisplatin was well tolerated. Due to early closure no conclusions can be reached on the relative merits; both arms showed good OS. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
18. The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.
- Author
-
Winata, Patrick, Williams, Marissa, McGowan, Eileen, Nassif, Najah, van Zandwijk, Nico, and Reid, Glen
- Subjects
- *
MICRORNA , *CANCER cells , *POLYMERASE chain reaction , *HYDROLYSIS , *MESOTHELIOMA - Abstract
Objective: MicroRNAs are frequently downregulated in cancer and restoring expression has tumour suppressive activity in tumour cells. Our recent phase I clinical trial investigated microRNA-based therapy in patients with malignant pleural mesothelioma. Treatment with TargomiRs, microRNA mimics with novel sequence packaged in EGFR antibody-targeted bacterial minicells, revealed clear signs of clinical activity. In order to detect delivery of microRNA mimics to tumour cells in future clinical trials, we tested hydrolysis probe-based assays specific for the sequence of the novel mimics in transfected mesothelioma cell lines using RT-qPCR. Results: The custom assays efficiently and specifically amplified the consensus mimics. However, we found that these assays gave a signal when total RNA from untransfected and control mimic-transfected cells were used as templates. Further investigation revealed that the reverse transcription step using stem-loop primers appeared to introduce substantial non-specific amplification with either total RNA or synthetic RNA templates. This suggests that reverse transcription using stem-loop primers suffers from an intrinsic lack of specificity for the detection of highly similar microRNAs in the same family, especially when analysing total RNA. These results suggest that RT-qPCR is unlikely to be an effective means to detect delivery of microRNA mimic-based drugs to tumour cells in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
- Author
-
Linton, Anthony, Soeberg, Matthew, Broome, Richard, Kao, Steven, and van Zandwijk, Nico
- Subjects
- *
MESOTHELIOMA , *ASBESTOS & health , *EPIDEMIOLOGY , *SOCIOECONOMIC factors , *CANCER chemotherapy , *TREATMENT effectiveness , *PROGNOSIS - Abstract
ABSTRACT Background and objective Whilst the impact of clinicopathological factors on the prognosis of malignant pleural mesothelioma ( MPM) is well understood, socioeconomic and geographic factors have received less attention. We analysed the relationship between geographic and socioeconomic factors upon survival and treatment provision in a large series of patients with MPM. Methods We assessed MPM patients awarded compensation between 2002 and 2009 with additional MPM incidence data from the New South Wales ( NSW) Cancer Registry. The impact of geographic remoteness, distance from oncological multidisciplinary team ( MDT) and Index of Relative Socioeconomic Advantage and Disadvantage ( IRSAD) upon survival, clinical features and treatment received was analysed. Results We identified 910 patients (67% residing in major cities; 92% <50 km from MDT). Median overall survival was 10.0 months. On multivariate analysis, age >70 (hazard ratio ( HR) = 1.39), male gender ( HR =1.36), non-epithelioid histological subtype ( HR = 2.18) and IRSAD status by decreasing quintile ( HR = 1.06) were independent prognostic factors. There was no significant advantage for patients residing in major cities (10.6 months vs 8.8 months; P = 0.162) or within 50 km of MDT (10.3 months vs 7.8 months; P = 0.539). Patient's geographic location and distance to MDT did not impact chemotherapy, adjuvant radiotherapy or extrapleural pneumonectomy provision. Socioeconomically disadvantaged patients were significantly less likely to receive chemotherapy (37.4% vs 54.8%; P = 0.001). Conclusion This study provides evidence for differences in the treatment and survival according to socioeconomic status for compensated MPM patients in NSW. Further research is warranted to seek additional explanations for the differences noted by comparing the treatments and outcomes of compensated and non-compensated MPM patients in NSW. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?
- Author
-
Wright, Casey M., Kirschner, Michaela B., van Zandwijk, Nico, and Reid, Glen
- Subjects
- *
MESOTHELIOMA , *APOPTOSIS - Abstract
A letter to the editor is presented in response to the article "miR-1 induced growth arrest and apoptosis in malignant mesothelioma," in the November 2013 issue.
- Published
- 2013
- Full Text
- View/download PDF
21. Locoregional delivery of CAR-T cells in the clinic.
- Author
-
Sagnella, Sharon M., White, Amy L., Yeo, Dannel, Saxena, Payal, van Zandwijk, Nico, and Rasko, John E.J.
- Subjects
- *
T cells , *DRUG side effects , *CHIMERIC antigen receptors , *HEPATIC artery , *TUMOR antigens ,CENTRAL nervous system tumors - Abstract
Cellular therapies utilizing T cells expressing chimeric antigen receptors (CARs) have garnered significant interest due to their clinical success in hematological malignancies. Unfortunately, this success has not been replicated in solid tumors, with only a small fraction of patients achieving complete responses. A number of obstacles to effective CAR-T cell therapy in solid tumors have been identified including tumor antigen heterogeneity, poor T cell fitness and persistence, inefficient trafficking and inability to penetrate into the tumor, immune-related adverse events due to on-target/off-tumor toxicity, and the immunosuppressive tumor microenvironment. Many preclinical studies have focused on improvements to CAR design to try to overcome some of these hurdles. However, a growing body of work has also focused on the use of local and/or regional delivery of CAR-T cells as a means to overcome poor T cell trafficking and inefficient T cell penetration into tumors. Most trials that incorporate locoregional delivery of CAR-T cells have targeted tumors of the central nervous system - repurposing an Ommaya/Rickham reservoir for repeated delivery of cells directly to the tumor cavity or ventricles. Hepatic artery infusion is another technique used for locoregional delivery to hepatic tumors. Locoregional delivery theoretically permits increased numbers of CAR-T cells within the tumor while reducing the risk of immune-related systemic toxicity. Studies to date have been almost exclusively phase I. The growing body of evidence indicates that locoregional delivery of CAR-T cells is both safe and feasible. This review focuses specifically on the use of locoregional delivery of CAR-T cells in clinical trials. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
- Author
-
Yuen Yee Cheng, Wright, Casey M., Kirschner, Michaela B., Williams, Marissa, Sarun, Kadir H., Sytnyk, Vladimir, Leshchynska, Iryna, Edelman, J. James, Vallely, Michael P., McCaughan, Brian C., Klebe, Sonja, van Zandwijk, Nico, Lin, Ruby C. Y., and Reid, Glen
- Subjects
- *
CALCIUM-dependent potassium channels , *CELL migration , *MESOTHELIOMA , *MICRORNA , *MESOTHELIUM , *GENE expression - Abstract
Background: Malignant pleural mesothelioma (MPM) is an aggressive, locally invasive, cancer elicited by asbestos exposure and almost invariably a fatal diagnosis. To date, we are one of the leading laboratory that compared microRNA expression profiles in MPM and normal mesothelium samples in order to identify dysregulated microRNAs with functional roles in mesothelioma. We interrogated a significant collection of MPM tumors and normal pleural samples in our biobank in search for novel therapeutic targets. Methods: Utilizing mRNA-microRNA correlations based on differential gene expression using Gene Set Enrichment Analysis (GSEA), we systematically combined publicly available gene expression datasets with our own MPM data in order to identify candidate targets for MPM therapy. Results: We identified enrichment of target binding sites for the miR-17 and miR-30 families in both MPM tumors and cell lines. RT-qPCR revealed that members of both families were significantly downregulated in MPM tumors and cell lines. Interestingly, lower expression of miR-17-5p (P = 0.022) and miR-20a-5p (P = 0.026) was clearly associated with epithelioid histology. We interrogated the predicted targets of these differentially expressed microRNA families in MPM cell lines, and identified KCa1.1, a calcium-activated potassium channel subunit alpha 1 encoded by the KCNMA1 gene, as a target of miR-17-5p. KCa1.1 was overexpressed in MPM cells compared to the (normal) mesothelial line MeT-5A, and was also upregulated in patient tumor samples compared to normal mesothelium. Transfection of MPM cells with a miR-17-5p mimic or KCNMA1-specific siRNAs reduced mRNA expression of KCa1.1 and inhibited MPM cell migration. Similarly, treatment with paxilline, a small molecule inhibitor of KCa1.1, resulted in suppression of MPM cell migration. Conclusion: These functional data implicating KCa1.1 in MPM cell migration support our integrative approach using MPM gene expression datasets to identify novel and potentially druggable targets. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
- Author
-
Kao, Steven C, Kirschner, Michaela B, Cooper, Wendy A, Tran, Thang, Burgers, Sjaak, Wright, Casey, Korse, Tiny, van den Broek, Daan, Edelman, James, Vallely, Michael, McCaughan, Brian, Pavlakis, Nick, Clarke, Stephen, Molloy, Mark P, van Zandwijk, Nico, and Reid, Glen
- Subjects
- *
ANIMAL experimentation , *CELL lines , *ENZYME-linked immunosorbent assay , *GLYCOPROTEINS , *IMMUNOHISTOCHEMISTRY , *LUNG tumors , *MASS spectrometry , *MESOTHELIOMA , *MICE , *MULTIVARIATE analysis , *PROGNOSIS , *SURVIVAL , *PROTEOMICS , *PLEURAL tumors , *PROPORTIONAL hazards models , *RETROSPECTIVE studies , *TISSUE arrays - Abstract
Background: We aimed to identify prognostic blood biomarkers using proteomics-based approaches in malignant pleural mesothelioma (MPM).Methods: Plasma samples from 12 MPM patients were used for exploratory mass spectrometry and ELISA analyses. The significance of secreted protein acidic and rich in cysteine (SPARC) was examined in sera from a Dutch series (n=97). To determine the source of the circulating SPARC, we investigated SPARC expression in MPM tumours and healthy controls, as well as the expression and secretion from cell lines and xenografts.Results: Secreted protein acidic and rich in cysteine was identified as a putative prognostic marker in plasma. Validation in the Dutch series showed that the median survival was higher in patients with low SPARC compared with those with high SPARC (19.0 vs 8.8 months; P=0.01). In multivariate analyses, serum SPARC remained as an independent predictor (HR 1.55; P=0.05). In MPM tumour samples, SPARC was present in the tumour cells and stromal fibroblasts. Cellular SPARC expression was higher in 5 out of 7 cell lines compared with two immortalized mesothelial lines. Neither cell lines nor xenograft tumours secreted detectable SPARC.Conclusions: Low circulating SPARC was associated with favourable prognosis. Secreted protein acidic and rich in cysteine was present in both tumour cells and stromal fibroblasts; and our in vitro and in vivo experiments suggest that stromal fibroblasts are a potential source of circulating SPARC. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
24. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
- Author
-
Kirschner, Michaela B, Pulford, Emily, Hoda, Mir Alireza, Rozsas, Anita, Griggs, Kim, Cheng, Yuen Yee, Edelman, J James B, Kao, Steven C, Hyland, Rebecca, Dong, Yawen, László, Viktoria, Klikovits, Thomas, Vallely, Michael P, Grusch, Michael, Hegedus, Balazs, Dome, Balazs, Klepetko, Walter, van Zandwijk, Nico, Klebe, Sonja, and Reid, Glen
- Subjects
- *
PLEURA cancer , *FIBULINS , *ENZYME-linked immunosorbent assay , *MESOTHELIOMA , *BIOMARKERS , *XENOGRAFTS , *PROGNOSIS , *DIAGNOSIS , *PROTEIN metabolism , *ANIMAL experimentation , *MICE , *PLEURAL effusions , *CASE-control method , *PLEURAL tumors - Abstract
Background: Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies.Methods: ELISA was used to measure cellular and secreted FBLN3 in cell lines, in plasma of xenograft tumour-bearing mice, in plasma from two independent series of MPM and non-MPM patients and in pleural fluid from a third series. Diagnostic and prognostic potential of FBLN3 was assessed by receiver operating characteristics curve analysis and Kaplan-Meier method, respectively.Results: FBLN3 was expressed in all MPM and benign mesothelial cell lines tested, and a correlation was observed between cellular protein expression and secreted levels. Human FBLN3 was detectable in plasma of tumour-bearing mice, suggesting that MPM cells contribute to levels of circulating FBLN3. Plasma FBLN3 was significantly elevated in MPM patients from the Sydney cohort, but not the Vienna cohort, but the diagnostic accuracy was low (63%, (95% CI: 50.1-76.4) and 56% (95% CI: 41.5-71.0), respectively). Although FBLN3 levels in pleural effusions were not significantly different between cases and controls, FBLN3 levels in pleural effusion fluid were found to be independently associated with prognosis (hazard ratio of 9.92 (95% CI: 2.14-45.93)).Conclusions: These data confirm the potential prognostic value of pleural effusion FBLN3, but question the diagnostic value of this protein in MPM patients. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
25. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
- Author
-
Henderson, Douglas W., Reid, Glen, Kao, Steven C., van Zandwijk, Nico, and Klebe, Sonja
- Subjects
- *
MESOTHELIOMA , *MICRORNA , *AQUAPORINS , *SYNOVIOMA , *HISTOLOGY , *DIAGNOSIS - Abstract
Pleural malignant mesothelioma (MM) includes several unusual and even rare but distinctive histological subtypes, in addition to the usual subdivision into epithelioid, biphasic and sarcomatoid MM. Criteria for discrimination between fibrous pleuritis versus desmoplastic mesothelioma include evidence of neoplastic invasion for diagnosis of desmoplastic MM, but this histological assessment is complicated by the recently-described 'fake fat phenomenon' in cases of fibrous pleuritis. The distinction between biphasic and monophasic synovial sarcoma of the pleura versus biphasic and sarcomatoid MM can be problematical and is most cogently based upon molecular detection of the t(X;18) translocation, whereas a clear diagnosis of MM for a pleural tumour histologically resembling synovial sarcoma is favoured by a negative result for this translocation and, probably, microRNA evidence supportive of a diagnosis of MM. Aquaporin-1 (AQP1) is a molecule involved in the growth of MM cells, and yet is a factor reported to correlate with improved survival rates for MM with an epithelioid component, in comparison to AQP1-poor MM, as assessed from AQP1 expression by epithelioid MM cells only (apart from co-expression by stromal endothelial cells in addition to the tumour cells). Recent reports have also focused upon germline mutations in the BRCA1-associated protein 1 (BAP1), not only in cases of familial mesothelioma, but also BAP1 deletion in sporadic MM. Prognostic factors for MM include not only the histological subtypes, but other independent variables that include (among others), AQP1 expression by mesothelioma cells, the clinical status of the patient, the serum neutrophil:lymphocyte ratio and blood thrombocytosis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
26. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
- Author
-
Henderson, Douglas W., Reid, Glen, Kao, Steven C., van Zandwijk, Nico, and Sonja Klebe
- Subjects
- *
MESOTHELIOMA , *CYTOLOGY , *DIAGNOSTIC immunohistochemistry , *BIOPSY , *BIOMARKERS , *DIAGNOSIS - Abstract
The detection of neoplastic invasion remains the linchpin for a clear diagnosis of malignant mesothelioma. Cytology-only diagnosis of epithelioid mesothelioma on aspirated effusion fluid remains controversial. A major problem is poor sensitivity, although cytodiagnosis is achievable in many cases at a high order of specificity, especially when a large volume of effusion fluid is submitted for cytological evaluation, enabling the preparation of cell-block sections for immunohistochemical investigation and when the cytological findings can be correlated with imaging studies to assess the anatomical distribution of the lesion and evidence of nodularity of the pleural disorder and, in some cases, to demonstrate evidence of invasion. Although 'positive' and 'negative' immunohistochemical markers have proved remarkably effective in distinguishing between epithelioid mesothelioma and secondary carcinoma and other malignant tumours metastatic to serosal membranes, no mesothelial marker has 100% sensitivity and specificity for mesothelioma diagnosis, so that panels of 'positive' antibodies and markers with negative predictive value are required. At present, no tissue or serum marker (including the molecular detection of p16/CDKN2A) has been proved to have sufficient specificity, consistency and reproducibility that it can replace evidence of invasion as the decisive marker for diagnosis when there is any uncertainty concerning a diagnosis of epithelioid mesothelioma and in the case of atypical fibrous lesions of the pleura (especially collagen-rich lesions, namely fibrous pleuritis vs desmoplastic mesothelioma), in which even the assessment of invasion can be problematical as illustrated in part 2 of this review. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
27. Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM).
- Author
-
Wright, Casey M., Kirschner, Michaela B., Cheng, Yuen Yee, O'Byrne, Kenneth J., Gray, Steven G., Schelch, Karin, Hoda, Mir Alireza, Klebe, Sonja, McCaughan, Brian, van Zandwijk, Nico, and Reid, Glen
- Subjects
- *
RNA , *GENETIC code , *GENETIC regulation , *MESOTHELIOMA , *MOLECULAR biology , *ONCOLOGY , *CANCER diagnosis - Abstract
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer that is often diagnosed at an advanced stage and is characterized by a long latency period (20–40 years between initial exposure and diagnosis) and prior exposure to asbestos. Currently accurate diagnosis of MPM is difficult due to the lack of sensitive biomarkers and despite minor improvements in treatment, median survival rates do not exceed 12 months. Accumulating evidence suggests that aberrant expression of long non-coding RNAs (lncRNAs) play an important functional role in cancer biology. LncRNAs are a class of recently discovered non-protein coding RNAs >200 nucleotides in length with a role in regulating transcription. Here we used NCode long noncoding microarrays to identify differentially expressed lncRNAs potentially involved in MPM pathogenesis. High priority candidate lncRNAs were selected on the basis of statistical (P<0.05) and biological significance (>3-fold difference). Expression levels of 9 candidate lncRNAs were technically validated using RT-qPCR, and biologically validated in three independent test sets: (1) 57 archived MPM tissues obtained from extrapleural pneumonectomy patients, (2) 15 cryopreserved MPM and 3 benign pleura, and (3) an extended panel of 10 MPM cell lines. RT-qPCR analysis demonstrated consistent up-regulation of these lncRNAs in independent datasets. ROC curve analysis showed that two candidates were able to separate benign pleura and MPM with high sensitivity and specificity, and were associated with nodal metastases and survival following induction chemotherapy. These results suggest that lncRNAs have potential to serve as biomarkers in MPM. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
28. The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma
- Author
-
Linton, Anthony, Vardy, Janette, Clarke, Stephen, and van Zandwijk, Nico
- Subjects
- *
ASBESTOS & health , *MESOTHELIOMA risk factors , *CANCER diagnosis , *FIBERS , *DISEASE prevalence , *CHRYSOTILE , *ETIOLOGY of diseases - Abstract
Abstract: The relationship between asbestos exposure and malignant mesothelioma (MM) has been well established. Despite bans on asbestos use in an increasing number of nations, the prolonged latency from exposure to diagnosis, and the ongoing presence and use of these dangerous fibres, have led to the increasing prevalence of this deadly disease worldwide. Whilst occupational contact has been implicated in the bulk of diagnosed cases over the past 50 years, a significant proportion of disease has been linked to para-occupational, domestic and environmental exposure. In this review, we will provide an update on the impact of historical and ongoing asbestos contact in both occupational and non-occupational settings. Furthermore, we will address the unresolved controversies surrounding the use of chrysotile asbestos, the effect of gender and genetics on development of this disease, childhood mesothelioma and co-aetiological factors including SV40 exposure. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
29. Haemolysis during Sample Preparation Alters microRNA Content of Plasma.
- Author
-
Kirschner, Michaela B., Kao, Steven C., Edelman, J. James, Armstrong, Nicola J., Vallely, Michael P., van Zandwijk, Nico, and Reid, Glen
- Subjects
- *
HEMOLYSIS & hemolysins , *MICRORNA , *BLOOD plasma , *ERYTHROCYTES , *BIOMARKERS , *MESOTHELIOMA , *CORONARY disease , *PATIENTS - Abstract
The presence of cell-free microRNAs (miRNAs) has been detected in a range of body fluids. The miRNA content of plasma/ serum in particular has been proposed as a potential source of novel biomarkers for a number of diseases. Nevertheless, the quantification of miRNAs from plasma or serum is made difficult due to inefficient isolation and lack of consensus regarding the optimal reference miRNA. The effect of haemolysis on the quantification and normalisation of miRNAs in plasma has not been investigated in great detail. We found that levels of miR-16, a commonly used reference gene, showed little variation when measured in plasma samples from healthy volunteers or patients with malignant mesothelioma or coronary artery disease. Including samples with evidence of haemolysis led to variation in miR-16 levels and consequently decreased its ability to serve as a reference. The levels of miR-16 and miR-451, both present in significant levels in red blood cells, were proportional to the degree of haemolysis. Measurements of the level of these miRNAs in whole blood, plasma, red blood cells and peripheral blood mononuclear cells revealed that the miRNA content of red blood cells represents the major source of variation in miR-16 and miR-451 levels measured in plasma. Adding lysed red blood cells to non-haemolysed plasma allowed a cut-off level of free haemoglobin to be determined, below which miR-16 and miR-451 levels displayed little variation between individuals. In conclusion, increases in plasma miR-16 and miR-451 are caused by haemolysis. In the absence of haemolysis the levels of both miR-16 and miR-451 are sufficiently constant to serve as normalisers. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
30. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided
- Author
-
Kappers, Ingrid, van Sandick, Johanna W., Burgers, Sjaak A., Belderbos, José S.A., van Zandwijk, Nico, and Klomp, Houke M.
- Subjects
- *
LUNG surgery , *CANCER chemotherapy , *CANCER treatment , *SMALL cell lung cancer , *PNEUMONECTOMY , *CANCER radiotherapy , *HEALTH outcome assessment , *HOSPITAL records , *ANTINEOPLASTIC agents - Abstract
Abstract: Background: The role of surgery in the treatment of patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) is a hot topic. Since variable results of surgery versus radiotherapy after induction chemotherapy are being reported, this study aimed to analyze results of surgery after induction chemotherapy and to identify relevant factors influencing outcome in patients with stage IIIA NSCLC. Methods: Patients with stage IIIA (N2) NSCLC, treated with platinum-based induction chemotherapy between 1994 and 2006, were identified. By a retrospective review of hospital records, response to induction treatment, short-term outcome, recurrence of disease and survival were evaluated. Results: Ninety-nine patients, 66 men and 33 women, were identified. Median follow-up was 54 months (range 13–129). Median age at treatment was 62 (range 36–77). Mediastinal downstaging was seen in 32 patients. Forty-three patients received radical radiotherapy and 39 patients underwent surgery: 19 pneumonectomies, 19 lobectomies and one exploratory thoracotomy. Microscopic complete resection (R0) was reached in 30 patients. Pathological response to induction therapy was CR in 5%, PR in 59% and SD in 36%. Postoperative mortality was 3%. The 1-year mortality was 26% after pneumonectomy and 11% after lobectomy. Five-year survival after surgery was 28%, and was better after lobectomy than after pneumonectomy (43% versus 16%; p =0.03). Other factors as age, weight loss, clinical mediastinal downstaging, radicality, and histology did not substantially contribute to this difference. Conclusion: Type of surgical resection was the major factor influencing outcome in patients with stage IIIA (N2) NSCLC after induction chemotherapy. These results suggest that patients with stage IIIA (N2) NSCLC may benefit from surgical resection, as long as a lobectomy can be performed. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
31. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection
- Author
-
Kappers, Ingrid, van Sandick, Johanna W., Burgers, Jacques A., Belderbos, José S.A., Wouters, Michel W., van Zandwijk, Nico, and Klomp, Houke M.
- Subjects
- *
COMBINED modality therapy , *SMALL cell lung cancer , *SURGICAL excision , *CANCER chemotherapy , *CANCER radiotherapy , *RADIATION doses , *CLINICAL pathology , *PLATINUM , *METALS in medicine , *PATIENTS - Abstract
Abstract: Objective: Superior sulcus tumours (SSTs) or Pancoast tumours are preferably treated with chemoradiotherapy (CRT) followed by surgical resection. However, when followed by surgery, it is associated with an increased complication rate. This study aims to evaluate the efficacy and safety of a concurrent induction protocol of 66Gy radiotherapy with cisplatinum and evaluate the rationale for subsequent surgery. Methods: Patients with SST treated in our institute from 1994 to 2006 were identified. The preferred induction treatment consisted of accelerated radiation (66Gy in fractions of 2.75Gy) with concurrent daily cisplatinum 6mgm−2. Surgical resection was planned 4–6 weeks thereafter. Performance status, co-morbidity, clinical and pathological tumour stage, (response to) treatment and survival were reviewed. Survival analysis was performed using the Kaplan–Meier method. Results: Over these 12 years, 85 patients with Pancoast tumours, 57 men and 28 women, were referred. Mean follow-up was 42 months (range: 2–120 months). Twenty-five patients had stage IIB (29%), seven had stage IIIA (8%), 32 had stage IIIB (38%) and 21 had stage IV (25%). Of the 64 patients presenting with stage II or III disease, 38 medically operable patients with potentially resectable tumours received induction therapy. After restaging, 22 patients underwent resection. All resections were complete and local recurrences were not observed. In 13 patients (62%) a pathologic complete response was found. In most cases, pathologic response was not evident from radiological imaging. The morbidity of surgery after induction treatment was acceptable. There was no fatal toxicity or treatment-related mortality. The 2- and 5-year overall survival of this selected group was 70% and 37%, respectively. Conclusion: This schedule of induction therapy with high-dose radiation and concurrent cisplatinum was safe and highly effective in fit patients. At this time, pathologic complete response cannot be reliably recognised preoperatively, and better tools for response assessment are critical for more tailored treatment of patients with SST. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
32. Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target.
- Author
-
Ruiz, Mariälle I. Gallegos, Floor, Karijn, Roepman, Paul, Rodriguez, José A., Meijer, Gerrit A., Mooi, Wolter J., Jassem, Ewa, Niklinski, Jacek, Muley, Thomas, van Zandwijk, Nico, Smit, Egbert F., Beebe, Kristin, Neckers, Len, Ylstra, Bauke, and Giaccone, Giuseppe
- Subjects
- *
SMALL cell lung cancer , *GENE expression , *LUNG cancer diagnosis , *MOLECULAR genetics , *GENETIC regulation , *GENOMICS , *COMPARATIVE genomic hybridization , *MOLECULAR biology , *DNA microarrays , *CHROMOSOMES - Abstract
Background: Lung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer (NSCLC) represents 85% of all lung cancers. Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease. Methodology and Principal Findings: In an attempt to identify novel NSCLC related genes, we performed a genome-wide screening of chromosomal copy number changes affecting gene expression using microarray based comparative genomic hybridization and gene expression arrays on 32 radically resected tumor samples from stage I and II NSCLC patients. An integrative analysis tool was applied to determine whether chromosomal copy number affects gene expression. We identified a deletion on 14q32.2-33 as a common alteration in NSCLC (44%), which significantly influenced gene expression for HSP90, residing on 14q32. This deletion was correlated with better overall survival (P = 0.008), survival was also longer in patients whose tumors had low expression levels of HSP90. We extended the analysis to three independent validation sets of NSCLC patients, and confirmed low HSP90 expression to be related with longer overall survival (P = 0.003, P = 0.07 and P = 0.04). Furthermore, in vitro treatment with an HSP90 inhibitor had potent antiproliferative activity in NSCLC cell lines. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
33. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer.
- Author
-
Van Meerbeeck, Jan P., Kramer, Gijs W. P. M., Van Schil, Paul E. Y., Legrand, Catherine, Smit, Egbert F., Schramel, Franz, Tjan-Heijnen, Vivianne C., Biesma, Bonne, Debruyne, Channa, Van Zandwijk, Nico, Splinter, Ted A. W., and Giaccone, Giuseppe
- Subjects
- *
RADIOTHERAPY , *ONCOLOGIC surgery , *LUNG cancer , *CANCER treatment , *DRUG therapy - Abstract
Background Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. Methods Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. Results Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [CI] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% CI = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. Conclusion In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
34. Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion.
- Author
-
Kartachova, Marina S., Valdés Olmos, Renato A., Haas, Rick L. M., Hoebers, Frank J. P., Brekel, Michiel W., van Zandwijk, Nico, van Herk, Marcel, and Verheij, Marcel
- Subjects
- *
CANCER , *PATIENTS , *TISSUES , *ANNEXINS , *LYMPHOMAS - Abstract
Purpose: The purpose of this study was to map treatment-induced 99mTc-Hynic-rh-annexin V uptake in normal tissues using co-registration of SPECT and CT. Methods: Nineteen patients (11 male, 8 female, mean age 57 years) with various malignant tumours (12 lymphomas, four non-small cell lung cancers and three head and neck squamous cell carcinomas) underwent 99mTc-Hynic-rhannexin V scintigraphy and CT before and within 48 h after the start of anticancer therapy. SPECT and CT were performed separately, with the patient in a reproducible position. Volume-based automated and manual methods were used to match functional and anatomical data. SPECT/CT co-registration was used to evaluate treatment-induced changes in the normal structures. Results: A significant radiation field-related increase in early post-treatment 99mTc-Hynic-rh-annexin V uptake in salivary glands and bone marrow was detected in eight of nine patients. Radiation field-related increase in bone marrow activity above the baseline value was detected in all 13 irradiated patients. A minimal, symmetrical increase in activity in the salivary glands was detected after the initial course of platinum-based chemotherapy, and a diffuse prominent increase in 99mTc-Hynic-rh-annexin V in the bone marrow was detected in all cases. Precise delineation between the tumour and normal tissue tracer accumulation was accomplished in all cases using SPECT/CT co-registered volumes, enhanced by the "colourwash" technique. Conclusion: Mapping of early treatment-related changes in annexin V uptake by SPECT/CT co-registration permits accurate evaluation of tracer distribution in normal structures and precise delineation from tumour uptake. The associations between tracer distribution in the normal tissues and treatment regimen found in this study may contribute to the evaluation of dose-effect relations in various treatment schedules. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
35. Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy
- Author
-
Kramer, Gijsbert W.P.M., Legrand, Catherine L., van Schil, Paul, Uitterhoeve, Lon, Smit, Egbert F., Schramel, Franz, Biesma, Bonne, Tjan-Heijnen, Vivianne, van Zandwijk, Nico, Splinter, Ted, Giaccone, Giuseppe, and van Meerbeeck, Jan P.
- Subjects
- *
PHOTOTHERAPY , *RADIOTHERAPY , *LUNG cancer , *DRUG therapy - Abstract
Abstract: The aim of this study was to investigate the improvement of quality of radiotherapy and compliance to the protocol amendment of EORTC study 08941. The radiotherapy-specific data were analysed from 154 patients with stage IIIA-N2 Non-Small-Cell Lung Cancer who were actually irradiated after response to 3 cycles of platinum-based induction chemotherapy. The parameters of quality, assessed in 93 patients before and in 61 after protocol amendment, included: time interval between last chemotherapy course and start of thoracic radiotherapy, the use of a 3-D planning CT, dose and fractionation scheme to the primary tumour, the involved and uninvolved mediastinum, duration of radiotherapy and toxicity. A significant improvement of all quality parameters was noted, except for the overall treatment time, which decreased slightly. Protocol amendment resulted in an improvement of the quality and the compliance of most observed parameters, at the cost of some increase in overall treatment time. The latter reflects logistical problems rather than poor compliance. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
36. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response
- Author
-
Kartachova, Marina, Haas, Rick L.M., Valdés Olmos, Renato A., Hoebers, Frank J.P., van Zandwijk, Nico, and Verheij, Marcel
- Subjects
- *
APOPTOSIS , *ANNEXINS , *LYMPHOMAS , *DRUG therapy - Abstract
Anticancer therapy induces apoptosis in a dose- and time-dependent fashion. 99mTc-Hynic-rh-Annexin V scintigraphy (TAVS) enables non-invasive in vivo imaging of treatment-induced apoptosis. We identified the visual patterns of 99mTc-Hynic-rh-Annexin V tumour uptake and related these to treatment response.Thirty-three patients with malignant lymphoma (n=26), leukaemia (n=1) NSCLC (n=5), H&NSCC (n=1), scheduled for radiotherapy (n=27), platinum-based chemotherapy (n=5) or concurrent chemoradiation (n=1), underwent TAVS before and early after the start of treatment. Planar and SPECT images were visually examined to assess changes in tumour 99mTc-Hynic-rh-Annexin V uptake. Twenty-nine patients were eligible for further analysis. Annexin V uptake before (Ubaseline) and early after (Upost) the start of treatment was graded using a four-step scale: 0, absent; 1, weak; 2, moderate and 3, intense. The difference between these values (ΔU) was calculated and correlated to tumour response after therapy (Spearman rank correlation test).Weak to moderate Ubaseline was detected in 13/15 patients with a complete response and Upost was markedly increased in all these cases (ΔU range 1–3). Partial response (n=7) was associated with weak to moderate Ubaseline and a moderately increased Upost (ΔU range 1–2). In patients with stable disease (n=5), Ubaseline was predominantly weak, without considerable changes in uptake after the start of treatment (ΔU range 0–1). Finally, in case of progressive disease (n=2), either no tumour uptake or a decrease in Upost was detected (ΔU=-1). A statistically significant correlation was found between changes in 99mTc-Hynic-rh-Annexin V tumour uptake and clinical response (correlation coefficient=0.62; P<0.001).Complete or partial tumour response was associated with a marked increase of 99mTc Hynic-rh-Annexin V accumulation early during treatment compared to baseline values. In case of stable or progressive disease, pretreatment scans demonstrated predominantly low 99mTc Hynic-rh-Annexin V tumour uptake and no significant increase early after treatment. These results indicate that TAVS might be useful as a predictive test for treatment response. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
37. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.
- Author
-
Ruivenkamp, Claudia A.L., van Wezel, Tom, Zanon, Carlo, Stassen, Alphons P.M., Vlcek, Cestmir, Csikós, Tamás, Klous, Anita M., Tripodis, Nikos, Perrakis, Anastassis, Boerrigter, Lucie, Groot, Peter C., Lindeman, Jan, Mooi, Wolter J., Meijjer, Gerrit A., Scholten, Gert, Dauwerse, Hans, Paces, Vaclav, van Zandwijk, Nico, and van Ommen, Gert Jan B.
- Subjects
- *
CANCER , *MENDEL'S law , *GENE mapping - Abstract
Only a small proportion of cancers result from familial cancer syndromes with Mendelian inheritance. Nonfamilial, 'sporadic' cancers, which represent most cancer cases, also have a significant hereditary component, but the genes involved have low penetrance and are extremely difficult to detect. Therefore, mapping and cloning of quantitative trait loci (QTLs) for cancer susceptibility in animals could help identify homologous genes in humans. Several cancer-susceptibility QTLs have been mapped in mice and rats, but none have been cloned so far. Here we report the positional cloning of the mouse gene Scc1 (Susceptibility to colon cancer 1)[sup 6] and the identification of Ptprj, encoding a receptor-type protein tyrosine phosphatase, as the underlying gene. In human colon, lung and breast cancers, we show frequent deletion of PTPRJ, allelic imbalance in loss of heterozygosity (LOH) and missense mutations. Our data suggest that PTPRJ is relevant to the development of several different human cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
38. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
- Author
-
de Bree E, van Ruth S, Baas P, Rutgers EJT, van Zandwijk N, Witkamp AJ, Zoetmulder FAN, de Bree, Eelco, van Ruth, Serge, Baas, Paul, Rutgers, Emiel J Th, van Zandwijk, Nico, Witkamp, Arjen J, and Zoetmulder, Frans A N
- Abstract
Study Objectives: No established curative treatment is available for pleural thymoma metastases and malignant pleural mesothelioma (MPM). Recently, peritoneal malignancies have been treated by cytoreductive surgery and intraoperative hyperthermic intracavitary perfusion chemotherapy (HIPEC). We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity.Design: Patients with pleural thymoma metastases or early-stage MPM were enrolled in a feasibility study. Morbidity, recurrence, and survival rates were recorded.Setting: The Netherlands Cancer Institute.Patients: Three patients with pleural thymoma metastases and 11 patients with pleural mesothelioma were treated.Interventions: Cytoreductive surgery and intraoperative hyperthermic intrathoracic perfusion chemotherapy (HITHOC) with cisplatin and adriamycin were performed. The mesothelioma patients received adjuvant radiotherapy on the thoracotomy wound and drainage tracts.Measurements and Results: Morbidity and mortality rates were 47% and 0%, respectively. Reoperation was necessary in four cases. Severe chemotherapy-related complications were not observed. A solitary mediastinal and a contralateral pleural thymoma recurrence were successfully treated by radiotherapy and a contralateral HITHOC procedure. All thymoma patients were alive and free of disease after a mean follow-up period of 18 months. After a mean follow-up period of 7.4 months, nine mesothelioma patients are alive. Two mesothelioma patients died of contralateral pleural and peritoneal recurrent disease, while one patient is alive with locoregional recurrence.Conclusions: Cytoreductive surgery and HITHOC with cisplatin and adriamycin is feasible in patients with pleural thymoma metastases and early-stage MPM, and is associated with acceptable morbidity rates. Early data on locoregional disease control are encouraging, and a phase II study will be conducted. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
39. Cytoreductive Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy in Patients With Malignant Mesothelioma or Pleural Metastases of Thymoma.
- Author
-
de Bree, Eelco, van Ruth, Serge, Baas, Paul, Th. Rutgers, Emiel J., van Zandwijk, Nico, Witkamp, Arjen J., and Zoetmulder, Fran A.N.
- Subjects
- *
MESOTHELIOMA , *METASTASIS , *SURGERY , *DRUG therapy , *PATIENTS - Abstract
Study objectives: No established curative treatment is available for pleural thymoma metastases and malignant pleural mesothelioma (MPM). Recently, peritoneal malignancies have been treated by cytoreductive surgery and intraoperative hyperthermic intracavitary perfusion chemotherapy (HIPEC). We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity. Design: Patients with pleural thymoma metastases or early-stage MPM were enrolled in a feasibility study. Morbidity, recurrence, and survival rates were recorded. Setting: The Netherlands Cancer Institute. Patients: Three patients with pleural thymoma metastases and 11 patients with pleural mesothelioma were treated. Interventions: Cytoreductive surgery and intraoperative hyperthermic intrathoracic perfusion chemotherapy (HITHOC) with cisplatin and adriamycin were performed. The mesothelioma patients received adjuvant radiotherapy on the thoracotomy wound and drainage tracts. Measurements and results: Morbidity and mortality rates were 47% and 0%, respectively. Reoperation was necessary in four cases. Severe chemotherapy-related complications were not observed. A solitary mediastinal and a contralateral pleural thymoma recurrence were successfully treated by radiotherapy and a contralateral HITHOC procedure. All thymoma patients were alive and free of disease after a mean follow-up period of 18 months. After a mean follow-up period of 7.4 months, nine mesothelioma patients are alive. Two mesothelioma patients died of contralateral pleural and peritoneal recurrent disease, while one patient is alive with locoregional recurrence. Conclusions: Cytoreductive surgery and HITHOC with cisplatin and adriamycin is feasible in patients with pleural thymoma metastases and early-stage MPM, and is associated with acceptable morbidity rates. Early data on locoregional disease control are encouraging, and a phase II study will be conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
40. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
- Author
-
Schouwink, Hugo, Rutgers, Emiel T., van der Sijp, Joost, Oppelaar, Hugo, van Zandwijk, Nico, van Veen, Robert, Burgers, Sjaak, Stewart, Fiona A., Zoetmulder, Frans, Baas, Paul, Schouwink, H, Rutgers, E T, van der Sijp, J, Oppelaar, H, van Zandwijk, N, van Veen, R, Burgers, S, Stewart, F A, Zoetmulder, F, and Baas, P
- Subjects
- *
PHOTOCHEMOTHERAPY , *SURGICAL complications , *TUMORS , *COMBINED modality therapy , *COMPARATIVE studies , *DRUG administration , *DOSE-effect relationship in pharmacology , *RESEARCH methodology , *INTRAOPERATIVE care , *MEDICAL cooperation , *MESOTHELIOMA , *PNEUMONECTOMY , *PORPHYRINS , *RESEARCH , *TUMOR classification , *PLEURAL tumors , *EVALUATION research - Abstract
Objective: To determine the optimal administered dose of meta-tetrahydroxyphenylchlorin (mTHPC) for intraoperative photodynamic therapy (IPDT) in resected malignant pleural mesothelioma (MPM). The primary objective of this combination treatment was to improve local tumor control.Design: Phase I/II dose escalation study.Setting: Two Dutch cancer centers.Patients: The study included 28 patients (2 women, 26 men), with pathologically confirmed MPM. The mean age was 57 years (age range, 37 to 68 years), and the World Health Organization performance score was 0 to 1. Epithelial mesotheliomas were found in 17 patients, a sarcomatous mesothelioma was found in 1 patient, and mixed epithelial sarcomatous mesotheliomas were found in 10 patients.Methods: Patients were injected with 0.075 mg/kg (4 patients), 0.10 mg/kg (19 patients), or 0.15 mg/kg (5 patients) mTHPC 4 or 6 days before undergoing surgery and IPDT. Complete surgical resection (i.e., pleuropneumonectomy) was followed by integral illumination with monochromatic light of 652 nm (10 J/cm(2)). The real-time fluence rate measurements were performed using four isotropic detectors in the chest cavity to calculate the total light dose.Results: Dose-limiting toxicity was reached at the level of 0.15 mg/kg mTHPC. Three patients died in the perioperative period, and one death was directly related to photodynamic therapy. Real-time dosimetry identified 12 patients in whom additional illumination had to be given to the diaphragmatic sinuses, which were unavoidably shielded during integral illumination. In two patients, illumination was cancelled due to the insufficient resectability of the tumor. The median survival time for all 28 patients was 10 months. Local tumor control, 9 months after treatment, was achieved in 13 of the 26 patients treated with IPDT.Conclusion: IPDT using mTHPC, combined with a pleuropneumonectomy, resulted in local control of disease in 50% of the treated cases. The considerable toxicity associated with the procedure, however, precludes its recommendation for widespread use. Stricter patient selection and improvements of the IPDT technique may reduce the toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF
41. The MARS feasibility trial: conclusions not supported by data
- Author
-
Weder, Walter, Stahel, Rolf A, Baas, Paul, Dafni, Urania, de Perrot, Marc, McCaughan, Brian C, Nakano, Takashi, Pass, Harvey I, Robinson, Bruce WS, Rusch, Valerie W, Sugarbaker, David J, and van Zandwijk, Nico
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.